Home » Topics » Regulatory » EMA

EMA
RSS

EMEA recommends temporary suspension of Acomplia marketing authorization in obese patients

Oct. 24, 2008

EMEA withdraws marketing authorization for Protopy in the European Union

Oct. 9, 2008

CHMP recommends variations to marketing authorization of Cancidas

Sep. 30, 2008

CHMP recommends marketing authorization for Azarga in open-angle glaucoma

Sep. 30, 2008

GSK withdraws European MAA for Quintanrix vaccine

Sep. 3, 2008

EMEA presents an update on reports of PML in MS patients treated with Tysabri

Aug. 14, 2008

CHMP recommends marketing authorization for GSK's prepandemic influenza vaccine

July 30, 2008

Anticoagulant Xarelto recommended for approval in E.U.; NDA submitted in U.S.

July 30, 2008

CHMP recommends refusal of Santhera's MAA for Sovrima in Friedreich's ataxia

July 30, 2008

CHMP adopts negative opinion for Howmedica's Opgenra

July 4, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...